⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 22, 2024ACS Medicinal Chemistry Letters

Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption

Kushvinder Kumar Yoshikazu Honda‐Okubo Isaac G. Sakala Kamal Singh Nikolai Petrovsky Deepak B. Salunke

View Full Paper

Ask AI

Bookmark

Share

Abstract

Toll-like receptor (TLR)-7/8 agonists are promising candidates for the development of new-generation vaccine adjuvants. Adsorption of TLR7/8 agonists on aluminum salts (alum) may further enhance vaccine immunogenicity. Evaluation of the adjuvanticity of the most active dual TLR7/8 agonists, 1-(3-(aminomethyl)benzyl)-2-butyl-1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kumar et al. (2024) studied this question.

synapsesocial.com/papers/68e5f73ab6db64358758bcd5 https://doi.org/10.1021/acsmedchemlett.4c00200

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Design and Synthesis of Polyphenolic Imidazo[4,5-<i>c</i>]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity2024 · 17 citations
2The scientific journey of a novel adjuvant (AS37) from bench to bedside2024 · 9 citations
3A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant2024 · 2 citations
4Dual <scp>TLR7</scp> /8 Activation by Dihydroxyimidazoquinoline Adjuvant Orchestrates <scp>NF</scp> ‐κβ‐ <scp>iNOS</scp> ‐Driven Th1 Immunity and Durable Protection Against <i>Leishmania donovani</i>Original Research · 2026
5TLR7/8 agonist-chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development†2025